Small Molecule Insulin-Regulated Aminopeptidase Inhibitors From In Silico Screening In 2008, Siew Chai and her group in Australia disclosed the first generation of drug-like small molecular weight inhibitors of IRAP (Albiston et al., 2008)
Currently, cellular senescence is understood as the response of cells to stress induced by both endogenous and exogenous factors, such as oncogenic factors, and genotoxic stress, telomere dysfunction, or mitochondrial degradation [11]
These findings provide a solid mechanistic foundation for the future development of BPC157-based or sequential therapeutic agents targeted at enhancing vascular repair
Mice were started on intraperitoneal injection (ip) of copper-free GHK (Peptide Sciences, Henderson, NV ) at a dose of 7.5 mg/kg ( n = 8), or ip saline ( n = 12), twice daily for five days
The main ongoing studies: REDEFINE 1 , Phase 3 obesity without T2D (results 20242025, preliminarily 25.3 %) REDEFINE 2 , Phase 3 obesity + T2D REDEFINE 3 , Phase 3 cardiovascular outcome trial (n~7000) Stand-alone clinical development of Cagrilintide is limited , Novo Nordisk is primarily investing in the CagriSema combination
